0109 GMT - Pro Medicus keeps its bull at Morgans despite the broker shifting its valuation model to one that prioritizes achievability over optimism. Maintaining a buy rating on Australian imaging-tech provider, analyst Iain Wilkie says that he is simply rebasing expectations to levels he is confident it can meet or beat. He tells clients in a note that the new model is more sensitive to the timing of contract implementations and reflects a materially stronger Australian dollar. Wilkie says recent contract announcements have confirmed demand and pricing power. Morgans cuts its target price 24% to A$210.00. Shares are down 1.3% at A$146.74. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 19, 2026 21:09 ET (01:09 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.